Zhejiang East Asia Pharmaceutical Balance Sheet Health
Financial Health criteria checks 4/6
Zhejiang East Asia Pharmaceutical has a total shareholder equity of CN¥2.0B and total debt of CN¥749.7M, which brings its debt-to-equity ratio to 37.1%. Its total assets and total liabilities are CN¥3.5B and CN¥1.5B respectively. Zhejiang East Asia Pharmaceutical's EBIT is CN¥72.5M making its interest coverage ratio -8.1. It has cash and short-term investments of CN¥294.0M.
Key information
37.1%
Debt to equity ratio
CN¥749.67m
Debt
| Interest coverage ratio | -8.1x |
| Cash | CN¥293.98m |
| Equity | CN¥2.02b |
| Total liabilities | CN¥1.50b |
| Total assets | CN¥3.52b |
Recent financial health updates
No updates
Recent updates
Zhejiang East Asia Pharmaceutical's (SHSE:605177) Shareholders Have More To Worry About Than Only Soft Earnings
Nov 06
Zhejiang East Asia Pharmaceutical Co., Ltd.'s (SHSE:605177) Shares Lagging The Market But So Is The Business
Oct 02Zhejiang East Asia Pharmaceutical's (SHSE:605177) Solid Profits Have Weak Fundamentals
May 06Zhejiang East Asia Pharmaceutical Co., Ltd. (SHSE:605177) Stock Catapults 26% Though Its Price And Business Still Lag The Market
Apr 23Take Care Before Diving Into The Deep End On Zhejiang East Asia Pharmaceutical Co., Ltd. (SHSE:605177)
Feb 28Financial Position Analysis
Short Term Liabilities: 605177's short term assets (CN¥1.6B) exceed its short term liabilities (CN¥740.5M).
Long Term Liabilities: 605177's short term assets (CN¥1.6B) exceed its long term liabilities (CN¥756.6M).
Debt to Equity History and Analysis
Debt Level: 605177's net debt to equity ratio (22.6%) is considered satisfactory.
Reducing Debt: 605177's debt to equity ratio has increased from 4.5% to 37.1% over the past 5 years.
Debt Coverage: 605177's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 605177 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 17:21 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhejiang East Asia Pharmaceutical Co., Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xiao Wei Lin | Everbright Securities Co. Ltd. |
| Mingrui Wang | Everbright Securities Co. Ltd. |